JP2017532294A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017532294A5 JP2017532294A5 JP2017510289A JP2017510289A JP2017532294A5 JP 2017532294 A5 JP2017532294 A5 JP 2017532294A5 JP 2017510289 A JP2017510289 A JP 2017510289A JP 2017510289 A JP2017510289 A JP 2017510289A JP 2017532294 A5 JP2017532294 A5 JP 2017532294A5
- Authority
- JP
- Japan
- Prior art keywords
- och
- phenyl
- compound
- chch
- sch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 33
- -1 methoxyphenyl Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 14
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 11
- 101150065749 Churc1 gene Proteins 0.000 claims 11
- 102100038239 Protein Churchill Human genes 0.000 claims 11
- 125000004076 pyridyl group Chemical group 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 8
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 125000001207 fluorophenyl group Chemical group 0.000 claims 3
- 125000003566 oxetanyl group Chemical group 0.000 claims 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 3
- 125000003003 spiro group Chemical group 0.000 claims 3
- 125000000335 thiazolyl group Chemical group 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 101100167062 Caenorhabditis elegans chch-3 gene Proteins 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000005869 (methoxyethoxy)methanyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000003944 tolyl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462039622P | 2014-08-20 | 2014-08-20 | |
| US62/039,622 | 2014-08-20 | ||
| PCT/US2015/046005 WO2016028959A1 (en) | 2014-08-20 | 2015-08-20 | Substituted bicyclic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017532294A JP2017532294A (ja) | 2017-11-02 |
| JP2017532294A5 true JP2017532294A5 (enExample) | 2018-09-27 |
| JP6607924B2 JP6607924B2 (ja) | 2019-11-20 |
Family
ID=54012322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017510289A Active JP6607924B2 (ja) | 2014-08-20 | 2015-08-20 | 置換二環式化合物 |
Country Status (34)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR101591A1 (es) * | 2014-08-20 | 2016-12-28 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos |
| ES2859478T3 (es) * | 2016-09-02 | 2021-10-04 | Bristol Myers Squibb Co | Compuestos heterocíclicos tricíclicos sustituidos |
| CA3066423A1 (en) * | 2017-06-14 | 2018-12-20 | Trevena, Inc. | Compounds for modulating s1p1 activity and methods of using the same |
| US11059784B2 (en) * | 2017-08-09 | 2021-07-13 | Bristol-Myers Squibb Company | Oxime ether compounds |
| WO2019032632A1 (en) | 2017-08-09 | 2019-02-14 | Bristol-Myers Squibb Company | ALKYLPHENYL COMPOUNDS |
| MX2022005766A (es) | 2019-11-19 | 2022-08-08 | Trevena Inc | Compuestos y métodos para la preparación de compuestos moduladores de esfingosina 1-fosfato tipo 1 (s1p1). |
| JP7653447B2 (ja) * | 2020-03-27 | 2025-03-28 | レセプトス・リミテッド・ライアビリティ・カンパニー | スフィンゴシン１ホスフェート受容体モジュレーター |
| CN116903578B (zh) * | 2023-09-04 | 2023-11-24 | 江西省药品检验检测研究院 | 连钱草中的酚酸类化合物及其提取分离方法与应用 |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
| US6069143A (en) | 1994-12-20 | 2000-05-30 | Smithkline Beecham Corporation | Fibrinogen receptor antagonists |
| ATE441654T1 (de) | 2002-01-18 | 2009-09-15 | Merck & Co Inc | Edg-rezeptoragonisten |
| US20050070506A1 (en) | 2002-01-18 | 2005-03-31 | Doherty George A. | Selective s1p1/edg1 receptor agonists |
| AU2003202994B2 (en) | 2002-01-18 | 2007-11-22 | Merck Sharp & Dohme Corp. | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists |
| JP2005531506A (ja) | 2002-03-01 | 2005-10-20 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体作動薬としてのアミノアルキルホスホネートおよび関連化合物 |
| JP2005533058A (ja) | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート |
| AU2004251146A1 (en) | 2003-05-19 | 2005-01-06 | Irm, Llc | Immunosuppressant compounds and compositions |
| AU2004299456B2 (en) | 2003-12-17 | 2010-10-07 | Merck Sharp & Dohme Corp. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
| TW200538433A (en) | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
| JP2008517915A (ja) | 2004-10-22 | 2008-05-29 | メルク エンド カムパニー インコーポレーテッド | Ｓ１ｐ受容体アゴニストとしての２−（アリール）アザシクリルメチルカルボキシレート、スルホネート、ホスホネート、ホスフィネート及びヘテロ環 |
| MX2007009848A (es) * | 2005-02-14 | 2008-03-10 | Univ Virginia | Agonistas de esfingosina 1-fosfato comprendiendo cicloalcanos y heterociclos de 5 miembros substituidos por grupos amino y fenilo. |
| JP2008530197A (ja) | 2005-02-18 | 2008-08-07 | イノディア インク． | ４−ヒドロキシイソロイシンの類似体及びその使用 |
| EP1858889A1 (en) | 2005-03-08 | 2007-11-28 | Biota Scientific Management Pty. Ltd. | Bicyclic nucleosides and nucleotides as therapeutic agents |
| BRPI0609668A2 (pt) | 2005-03-23 | 2011-10-18 | Actelion Pharmaceuticals Ltd | composto, composição farmacêutica, e, uso de um composto |
| CN101203512A (zh) | 2005-04-22 | 2008-06-18 | 第一三共株式会社 | 杂环化合物 |
| JP2008545767A (ja) | 2005-06-08 | 2008-12-18 | ノバルティス アクチエンゲゼルシャフト | 多環式オキサジアゾールまたはイソキサゾールおよびｓｉｐ受容体リガンドとしてのそれらの使用 |
| JP2009506046A (ja) | 2005-08-23 | 2009-02-12 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 免疫抑制剤化合物および組成物 |
| EP1976513B1 (en) | 2006-01-06 | 2016-08-24 | Sunovion Pharmaceuticals Inc. | Cycloalkylamines as monoamine reuptake inhibitors |
| MX2008009579A (es) | 2006-01-27 | 2008-09-25 | Univ Virginia | Metodo para el tratamiento de dolor neuropatico. |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| US7790707B2 (en) | 2006-03-21 | 2010-09-07 | Epix Pharmaceuticals Inc. | S1P receptor modulating compounds and use thereof |
| EP2001472A2 (en) | 2006-03-23 | 2008-12-17 | Merck and Co., Inc. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| MX2008012738A (es) | 2006-04-03 | 2009-02-06 | Astellas Pharma Inc | Heterocompuesto. |
| JP2009269819A (ja) | 2006-08-25 | 2009-11-19 | Asahi Kasei Pharma Kk | アミン化合物 |
| SI2069335T1 (sl) | 2006-09-08 | 2013-04-30 | Actelion Pharmaceuticals Ltd. | Derivati piridin-3-ila kot imunomodulacijska sredstva |
| CN101610674A (zh) * | 2006-12-21 | 2009-12-23 | 艾博特公司 | 鞘氨醇-1-磷酸酯受体激动剂和拮抗剂化合物 |
| CA2672727A1 (en) * | 2006-12-21 | 2008-07-03 | Abbott Laboratories | Sphingosine-1-phosphate receptor agonist and antagonist compounds |
| US8217027B2 (en) | 2006-12-21 | 2012-07-10 | Abbott Laboratories | Sphingosine-1-phosphate receptor agonist and antagonist compounds |
| GB0625648D0 (en) | 2006-12-21 | 2007-01-31 | Glaxo Group Ltd | Compounds |
| JP2010521450A (ja) | 2007-03-16 | 2010-06-24 | アクテリオン ファーマシューティカルズ リミテッド | Ｓ１ｐ１／ｅｄｇ１受容体アゴニストとしてのアミノ−ピリジン誘導体 |
| EA201070422A1 (ru) | 2007-10-04 | 2010-12-30 | Мерк Сероно С.А. | Производные оксадиазола |
| CN101970430B (zh) | 2007-11-01 | 2013-05-08 | 埃科特莱茵药品有限公司 | 嘧啶衍生物 |
| GB0725105D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| PE20091339A1 (es) | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
| EP2280933B1 (en) | 2008-04-01 | 2013-07-24 | Theravance, Inc. | 2 -aminotetralin derivatives as mu opioid receptor antagonists |
| AU2009304596A1 (en) | 2008-10-17 | 2010-04-22 | Akaal Pharma Pty Ltd | S1P receptors modulators |
| WO2010065760A1 (en) | 2008-12-04 | 2010-06-10 | Exelixis, Inc. | Imidazo [1,2a] pyridine derivatives, their use as s1p1 agonists and methods for their production |
| CA2743397C (en) | 2008-12-18 | 2017-02-28 | Mathilde Muzerelle | Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis |
| EP2202232A1 (en) | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4-oxadiazole derivatives and their therapeutic use |
| EP2210890A1 (en) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
| WO2010085582A1 (en) | 2009-01-23 | 2010-07-29 | Bristol-Myers Squibb Company | Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases |
| WO2010085581A1 (en) | 2009-01-23 | 2010-07-29 | Bristol-Myers Squibb Company | Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases |
| WO2010085584A1 (en) | 2009-01-23 | 2010-07-29 | Bristol-Myers Squibb Company | Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists |
| EP2395986A1 (en) | 2009-02-10 | 2011-12-21 | Abbott Laboratories | Methods for preparing s1p receptor agonists and antagonists |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| CN102686571B (zh) * | 2009-10-29 | 2015-11-25 | 百时美施贵宝公司 | 三环杂环化合物 |
| TW201130488A (en) * | 2010-02-03 | 2011-09-16 | Daiichi Sankyo Co Ltd | Pyrrole compound |
| ES2548683T3 (es) | 2010-04-23 | 2015-10-20 | Bristol-Myers Squibb Company | Amidas del ácido 4-(5-isoxazolil o 5-pirrazolil-1,2,4-oxadiazol-3-il)-mandélico como agonistas de receptor de esfingosina-1-fosfato 1 |
| CN102260617B (zh) | 2010-05-25 | 2013-11-13 | 张孝忠 | 一种王浆特制酒及其制作工艺 |
| CN102260177A (zh) | 2010-05-25 | 2011-11-30 | 中国医学科学院药物研究所 | 丙二醇类衍生物、其制备方法和其药物组合物与用途 |
| CN103124727B (zh) | 2010-07-20 | 2015-03-25 | 百时美施贵宝公司 | 取代的3-苯基-1,2,4-噁二唑化合物 |
| WO2012040532A1 (en) | 2010-09-24 | 2012-03-29 | Bristol-Myers Squibb Company | Substituted oxadiazole compounds and their use as s1p1 agonists |
| WO2012061459A1 (en) | 2010-11-03 | 2012-05-10 | Bristol-Myers Squibb Company | Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases |
| CN102250035A (zh) | 2011-06-10 | 2011-11-23 | 北京富卡生物技术有限公司 | 二芳基取代-1，3，4-噁二唑化合物的合成方法和其药物用途 |
| JP5984051B2 (ja) | 2012-07-12 | 2016-09-06 | 株式会社Ｇｓユアサ | 電極体 |
| TWI631097B (zh) | 2012-07-27 | 2018-08-01 | 百健Ｍａ公司 | 作爲ｓ１ｐ調節劑及／或ａｔｘ調節劑之化合物 |
| US9115054B2 (en) | 2013-02-21 | 2015-08-25 | Bristol-Myers Squibb Company | Tetrahydronaphthalenyl compounds useful as sipi agonists |
| AR101591A1 (es) * | 2014-08-20 | 2016-12-28 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos |
-
2015
- 2015-08-19 AR ARP150102669A patent/AR101591A1/es unknown
- 2015-08-19 TW TW104127046A patent/TWI689487B/zh not_active IP Right Cessation
- 2015-08-19 UY UY0001036274A patent/UY36274A/es not_active Application Discontinuation
- 2015-08-19 MA MA40082A patent/MA40082B1/fr unknown
- 2015-08-20 RS RS20210902A patent/RS62118B1/sr unknown
- 2015-08-20 EP EP15756772.8A patent/EP3183242B1/en active Active
- 2015-08-20 SM SM20210391T patent/SMT202100391T1/it unknown
- 2015-08-20 US US14/831,439 patent/US9522888B2/en active Active
- 2015-08-20 CN CN201580056555.0A patent/CN107148409B/zh active Active
- 2015-08-20 PL PL15756772T patent/PL3183242T3/pl unknown
- 2015-08-20 DK DK15756772.8T patent/DK3183242T3/da active
- 2015-08-20 MY MYPI2017700513A patent/MY179783A/en unknown
- 2015-08-20 CA CA2958560A patent/CA2958560C/en active Active
- 2015-08-20 EA EA201790427A patent/EA032415B1/ru not_active IP Right Cessation
- 2015-08-20 PT PT157567728T patent/PT3183242T/pt unknown
- 2015-08-20 PE PE2017000226A patent/PE20170445A1/es unknown
- 2015-08-20 TN TN2017000026A patent/TN2017000026A1/en unknown
- 2015-08-20 AU AU2015305501A patent/AU2015305501B2/en active Active
- 2015-08-20 WO PCT/US2015/046005 patent/WO2016028959A1/en not_active Ceased
- 2015-08-20 HR HRP20211121TT patent/HRP20211121T1/hr unknown
- 2015-08-20 SI SI201531645T patent/SI3183242T1/sl unknown
- 2015-08-20 HU HUE15756772A patent/HUE055567T2/hu unknown
- 2015-08-20 JP JP2017510289A patent/JP6607924B2/ja active Active
- 2015-08-20 LT LTEP15756772.8T patent/LT3183242T/lt unknown
- 2015-08-20 SG SG11201701221SA patent/SG11201701221SA/en unknown
- 2015-08-20 KR KR1020177007115A patent/KR102559465B1/ko active Active
- 2015-08-20 ES ES15756772T patent/ES2877627T3/es active Active
- 2015-08-20 MX MX2017001855A patent/MX381458B/es unknown
-
2016
- 2016-10-28 US US15/337,843 patent/US9770459B2/en active Active
-
2017
- 2017-02-13 PH PH12017500261A patent/PH12017500261A1/en unknown
- 2017-02-15 CL CL2017000382A patent/CL2017000382A1/es unknown
- 2017-02-15 IL IL250613A patent/IL250613B/en active IP Right Grant
- 2017-02-17 ZA ZA2017/01210A patent/ZA201701210B/en unknown
- 2017-03-08 CO CONC2017/0002312A patent/CO2017002312A2/es unknown
- 2017-07-12 US US15/648,250 patent/US10166249B2/en active Active
-
2018
- 2018-11-13 US US16/188,444 patent/US10709719B2/en active Active
-
2020
- 2020-05-21 US US16/879,824 patent/US11058696B2/en active Active
-
2021
- 2021-05-04 US US17/307,138 patent/US11701373B2/en active Active
- 2021-07-20 CY CY20211100656T patent/CY1124355T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6952695B2 (ja) | インフルエンザウイルス複製の阻害剤、その適用方法および使用 | |
| JP2015514808A5 (enExample) | ||
| JP2016506369A5 (enExample) | ||
| JP2018516963A5 (enExample) | ||
| JP2018535963A5 (enExample) | ||
| JP2015504067A5 (enExample) | ||
| JP2016514719A5 (enExample) | ||
| JP2019509276A5 (enExample) | ||
| JP2018517746A5 (enExample) | ||
| JP2015501833A5 (enExample) | ||
| JP2016525130A5 (enExample) | ||
| JP2016517417A5 (enExample) | ||
| JP2017504650A5 (enExample) | ||
| JP2012533630A5 (enExample) | ||
| JP2013533883A5 (enExample) | ||
| JP2012519691A5 (enExample) | ||
| JP2016530259A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| RU2015127827A (ru) | Производные бензилиденгуанидина и их терапевтическое применение для лечения заболеваний, связанных с неправильным сворачиванием белков | |
| JP2013529210A5 (enExample) | ||
| JP2009526761A5 (enExample) | ||
| JP2017533968A5 (enExample) | ||
| JP2005526857A5 (enExample) | ||
| JP2016504400A5 (enExample) | ||
| JP2013510825A5 (enExample) |